Cytek Biosciences : November 2022 Investor Presentation

Credit Suisse Conference Terranea Resort

Dr. Wenbin Jiang, CEO

November 2022

Safe Harbor Statement

This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the size and growth of the cell analysis market; Cytek's anticipated total addressable market; Cytek's business and operational strategy; Cytek's prospective products; Cytek's business development plans and opportunities; Cytek's anticipated customer mix and collaborations plans; and objectives of management for future operations are forward looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements The words "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to global economic and market conditions; the continued impacts of COVID-19; supply chain risks and Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization; Cytek's ability to maintain, protect and enhance its intellectual property; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's own internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors.

This presentation contains adjusted EBITDA and adjusted gross margin, financial measures that are not in accordance with Generally Accepted Accounting Principles (GAAP). Reconciliations of adjusted EBITDA and adjusted gross margin to the most comparable GAAP measures are included at the end of this slide presentation. We present adjusted EBITDA and adjusted gross margin because we believe they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Cytek, Full Spectrum Profiling, FSP, Northern Lights, and cFluor are trademarks or registered trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders.

2

Cytek's Leadership Team

Wenbin Jiang, Ph.D.	Ming Yan, Ph.D.	Patrik Jeanmonod	Todd Garland
Chief Executive Officer	Chief Technology Officer	Chief Financial Officer	Chief Commercial Officer

Valerie Barnett	Chris Williams	Allen Poirson, Ph.D.	Paul Goodson
General Counsel	Chief Operating Officer	SVP, Marketing and Corporate Development	Head of Investor Relations

Maria Jaimes, M.D.	Connie Wedel	Mark Edinger	Melik Ulusu	Dave Kennedy
VP, Applications	Chief People Officer	VP, Scientific Affairs	VP, Operations &	VP, Global Sales & Service
			Integrated Supply Chain

3

Investing to Capture the Cell Analysis Opportunity

CE-IVDD

2022

Validated

Technology Platform

1,501

Units Placed

881

Publications

Broad Customer Base and Global Presence

900+

Customers

40+

Countries

Strong

Financial Profile

$155M $21M

TTM Revenue/

A-EBITDA

$342M

Cash

No debt

Tonbo

Cell

Sorter

Reagents

Northern Lights

Aurora

2021

2021

2020

2018

2017

4

Global Scale and Reach with Diversified Revenue Mix

Since launch of Aurora Series in 2017…

900+ Customers

550+ Employees

150+ Biopharma Companies

40+ Countries	Seattle
WW Applications, Service & Sales	Fremont
	(Headquarters)

San Diego

% Revenue by Industry 1

42%

58%

Academic and Government-Owned Institutions

Pharmaceutical and Biotechnology Companies, Distributors and CROs

Amsterdam

Bethesda	Wuxi
Tokyo

Shanghai

% Revenue by Region1

USA	EMEA	APAC
59%	24%	17%

1. YTD Q3 2022

5